The abstract is read at the publisher; the summary is JClub's.
An end-to-end RNA-therapy pipeline for inherited retinal diseases identified cryptic SDCCAG8, CEP290, and ABCA4 variants and found ssASOs that improved normal splicing in patient-derived models.
- Why it matters: Rare genetic disease management depends on definitive molecular diagnosis, and RNA therapeutics can directly modulate splicing, but scalable workflows linking diagnosis to therapy are needed.
- What they did: Genome sequencing uncovered three cryptic IRD variants; RT-PCR characterized SDCCAG8 pseudoexon inclusion, CEP290 aberrant splicing was reproduced on patient-derived fibroblasts, and 16 ssASOs were tested across fibroblasts, mutant minigenes in HeLa, and retinal organoids when available.
- The result: For each variant, at least one ssASO improved normal splicing and increased gene expression in patient-derived models, validating a translational workflow that connects diagnosis to personalized RNA-based therapy development.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.